ML
ATNM icon

Mayport LLC’s Actinium Pharmaceuticals ATNM Stock Holding History

Mayport LLC’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.9K Hold
22,000
– – ﹤0.01% 130
2025
Q4 		$29.9K Hold
22,000
– – 0.01% 111
2025
Q3 		$35.2K Buy
+22,000
New +$35.8K 0.01% 109

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mayport LLC's ATNM Position: Q1 2026 in Review

Mayport LLC held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 22,000 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #130.

Mayport LLC first reported a position in ATNM in Q3 2025 and has held it in 3 quarters since. The position peaked at $35.2K in Q3 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Mayport LLC held 22,000 shares of Actinium Pharmaceuticals worth $21.9K as of Q1 2026.
  • Mayport LLC left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of Mayport LLC's portfolio in Q1 2026, its #130 holding.
  • Mayport LLC first reported a position in Actinium Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Mayport LLC's Actinium Pharmaceuticals position peaked at $35.2K in Q3 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Mayport LLC's 13F filing for Q1 2026, filed 21 Apr 2026.